China approves Mauna Kea's CellVizio cancer imaging system

Wed, 12/19/2012 - 11:26am
Mass Device

Mauna Kea Technologies receives regulatory approval in China for its Cellvizio confocal endomicroscopy device and lands a partnership with Fujifilm China to develop the market there.

Mauna Kea Technologies logo

The China State Food & Drug Administration approved Mauna Kea Technologies' Cellvizio confocal endomicroscopy system, a device design to see cancer faster.

Mauna Kea Technologies launched a strategic partnership with Fujifilm Holdings (TSE:4901) subsidiary Fujifilm China Investment Co., Ltd., to develop its optical biopsy market throughout China in various indications, according to the press release.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.